
    
      Patients with a history of hypoparathyroidism will be randomized to receive placebo or study
      drug for 24 weeks, which will be injected daily in either thigh. During that time they will
      be monitored for safety (specifically, calcium levels in the blood and urine). In addition,
      the patients' intake of Vitamin D and calcium will be measured.
    
  